PTCA

OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share

Retrieved on: 
Thursday, March 7, 2024

-- Revenue hit record high at US$153.9 million, up 12.5% year-on-year

Key Points: 
  • -- Revenue hit record high at US$153.9 million, up 12.5% year-on-year
    -- Revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year, respectively.
  • In particular, revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year to US$115.4 million and US$14.7 million, respectively.
  • As at December 31, 2023, the Group was in a strong financial position with cash and bank balances amounting to US$255.8 million (2022: US$229.1 million).
  • Having considered future capital requirements, the Board has proposed a final dividend of HK10 cents per share in cash, as a token of appreciation for the continuous support of shareholders.

OrbusNeich Adds Drug-eluting Balloons in Product Portfolio Through Acquisition of Eucatech AG

Retrieved on: 
Thursday, November 23, 2023

Upon completion of the acquisition, Eucatech AG will become a wholly-owned subsidiary of the Group.

Key Points: 
  • Upon completion of the acquisition, Eucatech AG will become a wholly-owned subsidiary of the Group.
  • Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, "We are pleased to announce the acquisition of Eucatech AG, a company with two decades of experience and a shared mission with OrbusNeich.
  • We believe that this acquisition will enrich our product portfolio.
  • Therefore, the Group views this acquisition as a strategic move to reinforce its market presence and distribution network .

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

Retrieved on: 
Tuesday, July 18, 2023

"With ready-to-use products like bivalirudin, we're helping to deliver solutions that reduce complexity for healthcare providers—so they can focus on patient care."

Key Points: 
  • "With ready-to-use products like bivalirudin, we're helping to deliver solutions that reduce complexity for healthcare providers—so they can focus on patient care."
  • In May 2023, Endo executed agreements with MAIA Pharmaceuticals, Inc. and Gland Pharma Limited, India to commercialize ready-to-use bivalirudin in the U.S.
  • The infusion dose of bivalirudin injection may need to be reduced, and anticoagulant status monitored in patients with renal impairment.
  • Bivalirudin injection is indicated for use as an anticoagulant in patients undergoing PCI, including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

Retrieved on: 
Tuesday, July 18, 2023

"With ready-to-use products like bivalirudin, we're helping to deliver solutions that reduce complexity for healthcare providers—so they can focus on patient care."

Key Points: 
  • "With ready-to-use products like bivalirudin, we're helping to deliver solutions that reduce complexity for healthcare providers—so they can focus on patient care."
  • In May 2023, Endo executed agreements with MAIA Pharmaceuticals, Inc. and Gland Pharma Limited, India to commercialize ready-to-use bivalirudin in the U.S.
  • The infusion dose of bivalirudin injection may need to be reduced, and anticoagulant status monitored in patients with renal impairment.
  • Bivalirudin injection is indicated for use as an anticoagulant in patients undergoing PCI, including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval

Retrieved on: 
Wednesday, January 11, 2023

Enrollment of the SELUTION SLR coronary de novo study will begin in the US within the next few months.

Key Points: 
  • Enrollment of the SELUTION SLR coronary de novo study will begin in the US within the next few months.
  • This will complement the substantial experience that the company has already gained with the SELUTION DeNOVO trial in Europe (ClinicalTrials.gov Identifier: NCT04859985).
  • The study is powered to demonstrate superiority of SELUTION SLR drug-eluting balloon (DEB) over DES in coronary de novo artery disease.
  • "Treatment of de novo coronary arteries with drug-eluting balloons is a breakthrough in revascularization of coronary artery disease.

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval

Retrieved on: 
Tuesday, January 10, 2023

Enrollment of the SELUTION SLR coronary de novo study will begin in the US within the next few months.

Key Points: 
  • Enrollment of the SELUTION SLR coronary de novo study will begin in the US within the next few months.
  • This will complement the substantial experience that the company has already gained with the SELUTION DeNOVO trial in Europe (ClinicalTrials.gov Identifier: NCT04859985).
  • The study is powered to demonstrate superiority of SELUTION SLR drug-eluting balloon (DEB) over DES in coronary de novo artery disease.
  • "Treatment of de novo coronary arteries with drug-eluting balloons is a breakthrough in revascularization of coronary artery disease.

PTCA Drug Coated Balloon (DCB) Catheters Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023

The "PTCA Drug Coated Balloon (DCB) Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PTCA Drug Coated Balloon (DCB) Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The publisher's Medical Devices sector report, "PTCA Drug Coated Balloon (DCB) Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the PTCA Drug Coated Balloon (DCB) Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • A Drug Coated Balloon (DCB) Catheter is an anti-restenotic drug-coated PTCA balloon catheter intended to prevent re-narrowing of the coronary arteries.
  • Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Global Percutaneous Transluminal Coronary Angioplasty Balloon Catheters Market to 2027 - Featuring Abbott Laboratories, Biotronik, Cardinal Health and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022

The "Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters estimated at US$997.6 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2027, growing at a CAGR of 3.6% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $271.8 Million, While China is Forecast to Grow at 5.7% CAGR
    The Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters market in the U.S. is estimated at US$271.8 Million in the year 2020.
  • In the global Cutting Balloon Catheter segment, USA, Canada, Japan, China and Europe will drive the 2.8% CAGR estimated for this segment.

Global Percutaneous Transluminal Coronary Angioplasty Balloon Catheters Market Report to 2031 - Featuring Boston Scientific, Becton, Dickinson & Company, Ivascular and Ronstis Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022

The global percutaneous transluminal coronary angioplasty (PTCA) balloon catheters market was estimated to be $1,201.23 million in 2021 and is estimated to reach $1,848.76 million in 2031 with an expected CAGR of 4.4% from 2022 to 2031.

Key Points: 
  • The global percutaneous transluminal coronary angioplasty (PTCA) balloon catheters market was estimated to be $1,201.23 million in 2021 and is estimated to reach $1,848.76 million in 2031 with an expected CAGR of 4.4% from 2022 to 2031.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the percutaneous transluminal coronary angioplasty (ptca) balloon catheters market analysis from 2021 to 2031 to identify the prevailing percutaneous transluminal coronary angioplasty (ptca) balloon catheters market opportunities.
  • In-depth analysis of the percutaneous transluminal coronary angioplasty (ptca) balloon catheters market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global percutaneous transluminal coronary angioplasty (ptca) balloon catheters market trends, key players, market segments, application areas, and PTCA balloon catheters market opportunity growth strategies.

Microbot Medical Strengthens LIBERTY® Robotic System Portfolio with Acquisition of Novel FDA-Cleared Devices

Retrieved on: 
Friday, October 7, 2022

HINGHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced today, as a continuation of its recent regulatory and future commercialization activities, together with its strategic mission to enable accessibility to multiple endovascular procedures globally, that it has acquired the assets of privately-held Nitiloop Ltd. The acquisition includes the NovaCross™ family of Microcatheters (NovaCross CTO, NovaCross Xtreme and NovaCross BTK), a U.S. Food and Drug Administration (FDA) cleared family of medical devices intended to facilitate the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions (CTO), prior to PTCA or stent intervention.

Key Points: 
  • The NovaCross Microcatheter family, as a standalone device or when potentially integrated with the Companys One & Done technology, is expected to create a collection of procedure related kits that are customized for the LIBERTY Robotic System.
  • The LIBERTY Robotic System is the first-ever disposable endovascular robotic system with remote operation capabilities and small footprint designed to reduce the requirement of capital investment and Cath Lab space.
  • The Company believes the achievement of the LIBERTY Robotic System ecosystem will allow Microbot Medical to advance the adoption of robotics in the endovascular space, globally.
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.